{"id":"W3095389126","doi":"10.1182/blood-2020-136985","title":"Initial Clinical Activity and Safety of BFCR4350A, a FcRH5/CD3 T-Cell-Engaging Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Multiple myeloma; Medicine; Bispecific antibody; Refractory (planetary science); Antibody; Oncology; Daratumumab; Cancer research; Internal medicine; Bortezomib; Immunology; Monoclonal antibody; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006283215,0.0006145027,0.001139949,0.0002916094,0.0003647893,0.0005481048,0.0004163458,0.0005848068,0.003236988],"category_scores_gemma":[0.0005570512,0.000248263,0.0007108004,0.0004157455,0.0003597572,0.0004479693,0.000285751,0.00184968,0.0008336214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001152228,"about_ca_system_score_gemma":0.0007644392,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002204368,"about_ca_topic_score_gemma":0.004644947,"domain_scores_codex":[0.999761,0.00006745136,0.00001760514,0.00004866659,0.00004563352,0.0000595208],"domain_scores_gemma":[0.9996995,0.000044059,0.00006732973,0.0000297872,0.00002728349,0.0001320809],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.181146,0.0258724,0.02602562,0.001239598,0.001138688,0.0008846325,0.0007490672,0.00684381,0.2707678,0.0005132111,0.01710985,0.4677092],"study_design_scores_gemma":[0.08017263,0.6853136,0.1467623,0.0002147547,0.001438753,0.002409016,0.0001707986,0.004672701,0.05248924,0.0007107,0.02555538,0.00009026687],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904274,0.002814087,0.0006389823,0.000324003,0.00002826693,0.0006413095,0.001998343,0.0001705049,0.002957215],"genre_scores_gemma":[0.9929045,0.00119802,0.0007936302,0.0003787771,0.00002982473,0.0003908971,0.002519598,0.00003312752,0.001751702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003236988,"threshold_uncertainty_score":0.01082879,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0630330095473095,"score_gpt":0.3613555670925355,"score_spread":0.298322557545226,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}